Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations

Journal of Human Genetics

Volumn 61, Issue 2, 2016, Pages 119-127

  Jittikoon, Jiraphun ^a   Mahasirimongkol, Surakameth ^b   Charoenyingwattana, Angkana ^c   Chaikledkaew, Usa ^a   Tragulpiankit, Pramote ^a   Mangmool, Supachoke ^a   Inunchot, Wimala ^b   Somboonyosdes, Chayapol ^b   Wichukchinda, Nuanjun ^b   Sawanpanyalert, Pathom ^b   He, Yijing ^d   Mcleod, Howard L ^d   Chantratita, Wasun ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE 1A1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; CARRIER PROTEIN;

AFRICAN; ALLELE FREQUENCY OF DRUG ABSORPTION DISTRIBUTION METABOLISM AND ELIMINATION RELATED GENE; ARTICLE; ASIAN; CAUCASIAN; DRUG METABOLISM; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE MAP; HUMAN; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN CONTINENTAL ANCESTRY GROUP; BLACK PERSON; DRUG INACTIVATION; GENE FREQUENCY; GENETICS; PHARMACOGENETIC VARIANT; THAILAND;

AFRICAN CONTINENTAL ANCESTRY GROUP; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; HAPMAP PROJECT; HUMANS; INACTIVATION, METABOLIC; MEMBRANE TRANSPORT PROTEINS; PHARMACOGENOMIC VARIANTS; POLYMORPHISM, SINGLE NUCLEOTIDE; THAILAND;

EID: 84959274497     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2015.115     Document Type: Article

References (35)

1. Fernandez, C. A., Smith, C., Yang, W., Lorier, R., Crews, K. R., Kornegay, N., et al. Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin. Pharmacol. Ther. 92, 360-365 (2012)
2. Rosenberg, N. A., Pritchard, J. K., Weber, J. L., Cann, H. M., Kidd, K. K., Zhivotovsky, L. A., et al. Genetic structure of human populations. Science 298, 2381-2385 (2002)
3. Wang, L., McLeod, H. L., & Weinshilboum, R. M. Genomics and drug response. N. Engl. J. Med. 364, 1144-1153 (2011)
4. Aekplakorn, W., Sangthong, R., Kessomboon, P., Putwatana, P., Inthawong, R., Taneepanichskul, S., et al. Changes in prevalence, awareness, treatment and control of hypertension in Thai population, 2004-2009: Thai National Health Examination Survey III-IV. J. Hypertens. 30, 1734-1742 (2012)
5. Burmester, J. K., Sedova, M., Shapero, M. H., & Mansfield, E. DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol. Biol. 632, 99-124 (2010)
6. Tassaneeyakul, W., Mahatthanatrakul, W., Niwatananun, K., Na-Bangchang, K., Tawalee, A., Krikreangsak, N., et al. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab. Pharmacokinet. 21, 286-290 (2006)
7. Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Meneveau, N., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009)
8. Wilkinson, G. R. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352, 2211-2221 (2005)
9. Suwannasri, P., Thongnoppakhun, W., Pramyothin, P., Assawamakin, A., & Limwongse, C. Combination of multiplex PCR and DHPLC-based strategy for CYP2D6 genotyping scheme in Thais. Clin. Biochem. 44, 1144-1152 (2011)
10. Sachse, C., Brockmoller, J., Bauer, S., & Roots, I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284-295 (1997)
11. Qin, S., Shen, L., Zhang, A., Xie, J., Shen, W., Chen, L., et al. Systematic polymorphism analysis of the CYP2D6 gene in four different geographical Han populations in mainland China. Genomics 92, 152-158 (2008)
12. Mannheimer, B., Wettermark, B., Lundberg, M., Pettersson, H., von Bahr, C., & Eliasson, E. Nationwide drug-Dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-Dependent drug interactions. Br. J. Clin. Pharmacol. 69, 411-417 (2010)
13. Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z. Y., Kaminsky, L. S., Shenfield, G. M., et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6, 341-349 (1996)
14. Bae, J. W., Kim, H. K., Kim, J. H., Yang, S. I., Kim, M. J., Jang, C. G., et al. Allele and genotype frequencies of CYP2C9 in a Korean population. Br. J. Clin. Pharmacol. 60, 418-422 (2005)
15. Kuanprasert, S., Dettrairat, S., Palacajornsuk, P., Kunachiwa, W., & Phrommintikul, A. Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand. J. Med. Assoc. Thai. 92, 1597-1601 (2009)
16. Limdi, N. A., Wadelius, M., Cavallari, L., Eriksson, N., Crawford, D. C., Lee, M. T., et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115, 3827-3834 (2010)
17. Sangviroon, A., Panomvana, D., Tassaneeyakul, W., & Namchaisiri, J. Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin. Drug Metab. Pharmacokinet. 25, 531-538 (2010)
18. Roy, J. N., Lajoie, J., Zijenah, L. S., Barama, A., Poirier, C., Ward, B. J., et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab. Dispos. 33, 884-887 (2005)
19. Zhu, H. J., Yuan, S. H., Fang, Y., Sun, X. Z., Kong, H., & Ge, W. H. The effect of CYP3A5 polymorphism on dose-Adjusted cyclosporine concentration in renal transplant recipients: a meta-Analysis. Pharmacogenomics J. 11, 237-246 (2011)
20. Kukongviriyapan, V., Prawan, A., Tassaneyakul, W., Aiemsa-Ard, J., & Warasiha, B. Arylamine N-Acetyltransferase-2 genotypes in the Thai population. Br. J. Clin. Pharmacol. 55, 278-281 (2003)
21. Higuchi, N., Tahara, N., Yanagihara, K., Fukushima, K., Suyama, N., Inoue, Y., et al. NAT2 6A, a haplotype of the N-Acetyltransferase 2 gene, is an important biomarker for risk of anti-Tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J. Gastroenterol. 13, 6003-6008 (2007)
22. He, J., Qiu, Z., Li, N., Yu, Y., Lu, Y., Han, D., et al. Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. Eur. J. Clin. Pharmacol. 67, 701-707 (2011)
23. Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., et al. SLCO1B1 variants and statin-induced myopathy-A genomewide study. N. Engl. J. Med. 359, 789-799 (2008)
24. Di, Y. M., Chow, V. D., Yang, L. P., & Zhou, S. F. Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr. Drug Metab. 10, 754-780 (2009)
25. Zanger, U. M., Klein, K., Saussele, T., Blievernicht, J., Hofmann, M. H., & Schwab, M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8, 743-759 (2007)
26. Daily, E. B., & Aquilante, C. L. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 10, 1489-1510 (2009)
27. Higashi, M. K., Veenstra, D. L., Kondo, L. M., Wittkowsky, A. K., Srinouanprachanh, S. L., Farin, F. M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002)
28. Li-Wan-Po, A., Girard, T., Farndon, P., Cooley, C., & Lithgow, J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19 17. Br. J. Clin. Pharmacol. 69, 222-230 (2010)
29. McAlpine, D. E., Biernacka, J. M., Mrazek, D. A., O'Kane, D. J., Stevens, S. R., Langman, L. J., et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther. Drug Monit. 33, 14-20 (2011)
30. Ross, K. A., Bigham, A. W., Edwards, M., Gozdzik, A., Suarez-Kurtz, G., & Parra, E. J. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J. Hum. Genet. 55, 582-589 (2010)
31. Klepstad, P., Dale, O., Skorpen, F., Borchgrevink, P. C., & Kaasa, S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol. Scand. 49, 902-908 (2005)
32. Chamorro, J. G., Castagnino, J. P., Musella, R. M., Nogueras, M., Aranda, F. M., Frias, A., et al. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J. Gastroenterol. Hepatol. 28, 323-328 (2013)
33. Krynetski, E. Y., Schuetz, J. D., Galpin, A. J., Pui, C. H., Relling, M. V., & Evans, W. E. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc. Natl Acad. Sci. USA 92, 949-953 (1995)
34. Sugatani, J. Function, genetic polymorphism, and transcriptional regulation of human UDP-glucuronosyltransferase (UGT) 1A1. Drug Metab. Pharmacokinet. 28, 83-92 (2013)
35. Gerloff, T., Schaefer, M., Mwinyi, J., Johne, A., Sudhop, T., Lutjohann, D., et al. Influence of the SLCO1B1 1b and 5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels. Naunyn Schmiedebergs Arch. Pharmacol. 373, 45-50 (2006).